Pharma major Dr Reddy's Laboratories (DRL) today said it has launched Sumatriptan Injection USP in the US.
The injection is an autoinjector system for subcutaneous use. It is a therapeutic equivalent generic version of Imitrex Statdose Pen (sumatriptan succinate) and was launched in the US market today following approval by the United States Food & Drug Administration (USFDA), a company statement said here.
